Abstract
Background: Our studies in cirrhotic patients led to the hypothesis that increased hepatic asymmetric dimethyarginine (ADMA- an endogenous nitric oxide inhibitor), due to decreased dimethylarginine dimethylaminohydrolase-1 expression (DDAH1-hydrolizes ADMA), reduces eNOS activity and is associated with severity of portal hypertension. These data suggested that a DDAH-1 agonist may reduce portal pressure. FXR is a bile-acid responsive nuclear receptor previously shown to have hepatoprotective effects from bile duct ligation (BDL) injury in rats.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
